Source: https://www.bakerdonelson.com/publications/2188-the-judge-doth-reject-how-prepare-increased-judicial-scrutiny-corporate
Timestamp: 2019-04-25 08:06:07+00:00

Document:
This article was originally published by the American Bar Association.
Federal judges have historically accepted without much public commentary “global” settlements reached by government regulators and large corporations that resolve criminal and civil liability. In the past decade, judges have routinely approved settlements that have led to notable corporate compliance reform while simultaneously imposing significant fines and penalties against corporate defendants. Nuanced global settlements have been especially prevalent in the health care context, where defendant providers and suppliers seek to reach agreement with a host of government agencies in a manner that avoids some of the most drastic collateral consequences.
As revealed in current events, judges have begun to express concerns about the terms of global settlements in cases outside of the securities law context. Cases involving Orthofix International N.V. (“Orthofix”) and WakeMed Health and Hospitals (“WakeMed”) demonstrate how judges are beginning to conduct exacting reviews of corporate settlements in the health care arena. The precedent set in these cases potentially has enormous implications for defense counsel in major health care cases.
In June of 2012, medical device manufacturer Orthofix reached a global resolution with federal prosecutors under which the company agreed to: pay $34 million to resolve False Claims Act allegations, pay a $7.7 million criminal fine, and have one of its subsidiaries plead guilty to a felony obstruction offense. The False Claims Act case was initiated by a whistleblower who alleged that certain company sales reps had falsified certificates of medical necessity (CMN) when seeking Medicare reimbursement for several bone-growth stimulators. The criminal charge stemmed from Orthofix’s alleged failure to disclose material information to the government during a Medicare audit of its practices related to the CMNs. As part of the settlement, Orthofix agreed to enter into a far-reaching Corporate Integrity Agreement (CIA) with the Department of Health and Human Services (HHS), Office of Inspector General (OIG). In related criminal resolutions, several now-former Orthofix employees and contractors pleaded guilty to felony convictions for their activities, which included the payment of physician kickbacks and the falsification of patient medical records.
WakeMed, a North Carolina based non-profit health care system, became a law enforcement target after a 2007 audit identified one of its hospitals as having an inflated number of “zero-day stay” billings, under which inpatient stays lasting less than a day were improperly billed to Medicare. The government subsequently alleged that the hospital’s cardiac center had been improperly classifying patients for inpatient hospital stays—a practice that helped the hospital to receive approximately $1.2 million in overpayments between 2003 and 2010.
The hospital entered into global settlement negotiations that included a civil agreement to resolve False Claims Act charges, a two-year Deferred Prosecution Agreement (DPA), and a five-year Corporate Integrity Agreement (CIA). The hospital agreed to pay $8 million and to submit to a two-year probationary period under the DPA, during which time it would be subject to an independent auditor’s review. The WakeMed case has been viewed as unique, for while it not uncommon for health care providers to face civil False Claims Act charges for upcoding activities, it is rare for a large non-profit community hospital to also face criminal felony prosecution for such conduct.
It remains to be seen whether the Orthofix and WakeMed cases are aberrations, or if they portend a momentous shift in the resolution of corporate health care cases. Nevertheless, the mere prospect of increased judicial scrutiny of corporate settlement agreements in health care cases presents unique concerns for prosecutors and defense counsel alike.
Increased judicial scrutiny of settlements is an especially grave concern for health care providers and suppliers, who have faced intensified pressure to create a robust compliance culture as the government has made health care fraud an enforcement priority. Equipped with new legal tools and penalties authorized by the Affordable Care Act, the government enjoys enormous leverage in combating fraud at every level of the health care system. Given the complexity of the regulatory environment in which health care providers operate, it is not uncommon for even the most compliant provider groups to find themselves on the wrong end of the law. If corporate defendants had previously assumed that the judiciary would serve as a bulwark against prosecutorial overreach and be its best assurance of a balanced resolution, the Orthofix and WakeMed cases should give pause. It is now clear that defendants must be prepared for judges who will view their conduct with a more jaundiced eye.
Best Practices: What is a Corporate Defense Counsel to Do?
Argument: Upon reaching a settlement with the government, defense counsel will need to carefully consider how the agreement is structured and presented for judicial approval. Counsel should prepare a detailed argument that bolsters the merits of the proposed agreement and how it furthers the public interest—one of the most significant factors for reviewing judges. Among other things, emphasis should be placed upon the defendant’s cooperation with the government during the course of the investigation and going forward, and upon how the corporation has genuinely undertaken significant efforts to prevent the harm from recurring.
Education: In making the case for settlement, defense counsel should also be prepared to assume the role of assisting the judge in understanding his client’s unique circumstances and history and any peculiarities of the underlying law. While the harsh collateral consequences in the health care setting—which include loss of licensure, exclusion from federal programs, revocation of Medicare billing privileges, and FDA debarment—may be clear to health care providers, how they operate in a given case may not be readily apparent. For this reason, defense counsel should carefully brief these issues and explain how the collateral consequences would impact their clients and the communities they serve. This was critical in the WakeMed case, where Judge Boyle ultimately agreed to the use of a DPA after being informed of the consequences of exclusion.
Data: Satisfaction of the public interest is easy to express in the abstract, but difficult to convey through the nuts and bolts of a settlement agreement. For this reason, defense counsel should present relevant statistics that substantiate the advantages of the proposed agreement and why it includes or excludes certain components.
Disclosure: Transparency, both to the court and to the general public, is a quality that reviewing judges have come to expect. Judge Rakoff emphasized that judges cannot conduct a proper review upon “bare bones” submissions that reveal little about the factual underpinnings of the proposed settlement.14 On the other hand, it may be critical to preserve the confidentiality of certain aspects of the case that involve the company’s proprietary information. The extent of disclosure and the potential impact to the corporation’s reputation and its standing in subsequent lawsuits raise difficult, albeit critical, issues for defense counsel.
Penalties: Defense counsel should explain how the various penalties are interrelated and their real world impact on a corporation’s daily operations and the greater community.
Compliance: In arguing before the court, defense counsel should detail the past and future compliance reforms that the company has agreed to undertake. These reforms should accommodate the expectations of the various federal actors involved, including civil and criminal prosecutors, the OIG, state agencies and licensing authorities, etc. Defense counsel should also prepare their clients for the possibility that courts may expect to receive reports from the appointed monitor so that it is apprised of ongoing compliance efforts.
1 SEC v. Bank of America Corp., No. 09 Civ. 6829 (S.D.N.Y. Sept. 14, 2009); SEC v. Citigroup Global Markets Inc., No. 11 Civ. 7387 (S.D.N.Y. Nov. 28, 2011). See also Hon. Jed S. Rakoff, Are Settlements Sacrosanct?, 37 LITIG. 15 (Summer 2011).
2 Judge Rudolph Randa of the U.S. District Court for the Eastern District of Wisconsin cited Judge Rakoff’s Citigroup opinion when he temporarily held up a proposed deal between the SEC and the Koss Corporation. SEC v. Koss Corporation. No. 11-C-991 (E.D. Wis. Dec. 20, 2011) (letter to parties).; Judge Richard Leon of the U.S. District Court for the District of Columbia stymied the SEC’s proposed $10 million agreement with IBM in a civil case under the Foreign Corrupt Practices Act involving the bribery of Chinese and South Korean government officials. Judge Leon noted that he was one of “a growing number of district judges who are increasingly concerned” by the SEC’s settlement policies. Christopher W. Matthews, Judge Blasts IBM, SEC Bribery Settlement, WALL ST. J., Dec. 21, 2012, at B4.
3 Jef Feeley & Janelle Lawrence, Orthofix’s Settlement of Medicare Probe Rejected by Judge, BLOOMBERG NEWS (Sept. 6, 2012).
5 Transcript Excerpt of Sentencing Hearing at 2, United States v. Orthofix, Inc., No. 12-10169 (D. Mass. Dec. 18, 2012).
6 Anne Blythe & Joseph Neff, Judge Refuses to Accept WakeMed Settlement with Federal Prosecutors, THE NEWS & OBSERVER (Jan. 17, 2013).
7 Anne Blythe & Joseph Neff, WakeMed’s Medicare Settlement with Feds Would Allow Confidential Reports, THE NEWS & OBSERVER (Feb. 2, 2013).
8 Order of Judge Terrence W. Boyle, United States v. WakeMed, No. 5:12-CR-398-BO (Feb. 8, 2013).
11 In a recent speech, former Assistant Attorney General Lanny Breuer described DPAs as playing an essential role in the enforcement of corporate crime. Lanny A. Breuer, Assistant Attorney General, Criminal Division, Address to the New York City Bar Association (Sept. 13, 2012), available at http://www.justice.gov/criminal/pr/speeches/2012/crm-speech-1209131.html.
12 In WakeMed, the prosecutors stated, in a court memorandum that “[w]hile an individual convicted of an economic crime may face prison time as a sentence, a corporation convicted of the same offense may literally cease to exist as the result of a court order or as a practical impact of the conviction upon its business operations. Corporations also may be made up of thousands of individual employees, many of which had no part in any wrongdoing.” Anne Blyethe & Joseph Neff, WakeMed’s Medicare Settlement with Feds would Allow Confidential Reports, THE NEWS & OBSERVER (Feb. 2, 2013).
13 Robert Khuzami, the Director of the SEC’s Division of Enforcement, noted in a public statement that refusals of settlements agreements would “divert resources away from the investigation of other frauds and the recovery of losses suffered by other investors not before the court.” Robert Khuzami, Public Statement by SEC Staff: Court’s Refusal to Approve Settlement in Citigroup Case (Nov. 28, 2011).
14 Hon. Jed S. Rakoff, Are Settlements Sacrosanct?, 37 LITIG. 15, 17 (Summer 2011).
15 In his decision rejecting the Citigroup settlement, Judge Rakoff cited to a prior settlement reached between the SEC and Goldman Sachs in which Goldman “acknowledg[ed]” that it committed a “mistake” with respect to certain marketing materials—a mistake that it “regret[ted].” SEC v. Citigroup Global Markets Inc., 2011 WL 5903733, at * n.7 (S.D.N.Y. Nov. 28, 2011). Such language may serve as a model for striking the right balance between showing contrition without incurring future legal liability.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v.